Your browser doesn't support javascript.
loading
Economic Burden of Juvenile Idiopathic Arthritis in India.
Khatun, Moksuda; Datta, Debadyuti; Hazra, Avijit; Ghosh, Pramit; Selim, Muhammad Bin; Mondal, Rakesh.
Afiliación
  • Khatun M; Department of Pediatrics, Medical College Kolkata, Kolkata, West Bengal, India.
  • Datta D; Department of Pediatrics, NB Medical College, Kolkata, West Bengal, India.
  • Hazra A; Department of Pharmacology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India.
  • Ghosh P; Department of Community Medicine, Medical College Kolkata, Kolkata, West Bengal, India.
  • Selim MB; Department of Pediatrics, Kakdwip Super Speciality Hospital, Kolkata, West Bengal, India.
  • Mondal R; Department of Pediatrics, Medical College Kolkata, Kolkata, West Bengal, India. Correspondence to: Dr Rakesh Mondal, Pediatric Rheumatology Unit; Department of Pediatrics, Medical College Kolkata, West Bengal, India. ivanrakesh2001@gmail.com.
Indian Pediatr ; 58(1): 38-40, 2021 Jan 15.
Article en En | MEDLINE | ID: mdl-33034299
BACKGROUND: Published Indian studies on the economic burden of juvenile idiopathic arthritis (JIA) are lacking. METHODS: A prospective observational study recruited pediatric patients aged from 1 to 12 years with JIA in the pediatric rheumatology clinic of a public sector tertiary care hospital. Direct healthcare costs and indirect costs for transportation, accommodation of the caregivers, and productivity loss for work absenteeism were assessed. RESULTS: The proportions of direct annualized cost assessed in 60 patients (mean (SD) age 8.46 (2.24) year) spent on outpatient visits, blood tests, imaging investigations, other tests, medications and hospitalization were 0.85%, 12.8%, 9.0%, 2.9%, 41.7% and 32.7%, respectively. Direct healthcare costs for blood tests and medicine were lowest in oligoarticular JIA and highest in systemic onset JIA and (P=0.043 and 0.001 respectively). The direct and indirect costs were higher with the use of biologic agents (n=9) than in those without (n=51). CONCLUSION: JIA imposes considerable economic burden with the largest share attributable to medicines, and maximum in those with systemic onset JIA.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Juvenil Tipo de estudio: Health_economic_evaluation / Observational_studies Límite: Child / Humans País/Región como asunto: Asia Idioma: En Revista: Indian Pediatr Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: India
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Juvenil Tipo de estudio: Health_economic_evaluation / Observational_studies Límite: Child / Humans País/Región como asunto: Asia Idioma: En Revista: Indian Pediatr Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: India